1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Comparison of baseline characteristics, time of treatment stage, and clinical and radiologic outcomes between the good clinical outcome group and the poor clinical outcome group
CharacteristicPatientsP Value
Good Clinical Outcome (n = 103)Poor Clinical Outcome (n = 68)
Age (median) (IQR) (yr)73 (62–78)78 (66–83).007a
Male (No.) (%)55 (53.4)31 (45.6).317b
Diabetes mellitus (No.) (%)23 (22.3)17 (25.0).686b
Hypertension (No.) (%)59 (57.3)34 (50.0).349b
Dyslipidemia (No.) (%)14 (13.6)9 (13.2).947b
Atrial fibrillation (No.) (%)33 (32.0)15 (22.1).155b
CAOD (No.) (%)18 (17.5)6 (8.8).111b
Occlusion location (right) (No.) (%)47 (45.6)37 (54.4).261b
Initial NIHSS score (median) (IQR)10 (7–14)14 (12–18)<.001a
Time of treatment stage
 Symptom onset to hospital arrival (median) (IQR) (min)120 (46–330)122 (46–433).891a
 Door to puncture (median) (IQR) (min)108 (83–147)109 (83–157).595a
 Symptom onset to puncture (median) (IQR) (min)255 (160–515)254 (171–643).612a
 Procedure time (median) (IQR) (min)60 (44–85)65 (44–86).925a
Successful recanalization91 (88.3)52 (76.5).040b
  • Note:—CAOD indicates coronary artery occlusive disease.
  • ↵a P value obtained using the Mann-Whitney U test.
  • ↵b P value obtained using the Pearson χ2 test.